What's in Genuine Research Center, Egypt's pipeline?

Genuine Research Center, Egypt has 31 drugs in our index: 7 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 24 in Phase 1.

Which companies overlap with Genuine Research Center, Egypt's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Amneal Pharmaceuticals, LLC, Bayer, Assaf-Harofeh Medical Center, Azienda USL Reggio Emilia - IRCCS.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/genuine-research-center-egypt.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Genuine Research Center, Egypt — Portfolio Competitive Intelligence Brief

Genuine Research Center, Egypt pipeline: 7 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

7 marketed 0 filed 0 Phase 3 0 Phase 2 24 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Sovaldi	Sovaldi	marketed		Cereblon isoform 4, Genome polyprotein, NS5	Infectious Disease
Dexilant	Dexilant	marketed		Sterile alpha and TIR motif-containing protein 1, Cytosolic endo-beta-N-acetylglucosaminidase, Potassium-transporting ATPase	Gastroenterology
Singulair	Singulair	marketed		Cytochrome P450 2C8, Adenosine receptor A3, Cysteinyl leukotriene receptor 2	Respiratory
Epifasi: Human chorionic gonadotrophin	Epifasi: Human chorionic gonadotrophin	marketed
Nerkardou (5 mg) & (10 mg)	Nerkardou (5 mg) & (10 mg)	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-2	Rheumatology
Tamiflu®	Tamiflu®	marketed	Neuraminidase inhibitor	Influenza neuraminidase	Infectious Disease / Virology
Pregnyl: Human chorionic gonadotrophin	Pregnyl: Human chorionic gonadotrophin	marketed	Gonadotrophin	Luteinizing hormone receptor (LH receptor)	Reproductive/Fertility

Therapeutic area mix

Other · 21
Infectious Disease · 3
Infectious Disease / Virology · 1
Gastroenterology · 1
Reproductive/Fertility · 1
Respiratory · 1
Rheumatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 2 shared drug classes
Amneal Pharmaceuticals, LLC · 1 shared drug class
Bayer · 1 shared drug class
Assaf-Harofeh Medical Center · 1 shared drug class
Azienda USL Reggio Emilia - IRCCS · 1 shared drug class
Bausch & Lomb Incorporated · 1 shared drug class
Amzell · 1 shared drug class
Actavis Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Genuine Research Center, Egypt:

Cite this brief

Drug Landscape (2026). Genuine Research Center, Egypt — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/genuine-research-center-egypt. Accessed 2026-05-16.